The Outcomes of Concomitant Hypofractionated Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive Lymph Nodes.
darwish, S., Elkady, A. (2023). The Outcomes of Concomitant Hypofractionated Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive Lymph Nodes.. EKB Journal Management System, 7(3), 77-84. doi: 10.21608/jcbr.2023.227456.1310
sara A. darwish; Asmaa Elkady. "The Outcomes of Concomitant Hypofractionated Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive Lymph Nodes.". EKB Journal Management System, 7, 3, 2023, 77-84. doi: 10.21608/jcbr.2023.227456.1310
darwish, S., Elkady, A. (2023). 'The Outcomes of Concomitant Hypofractionated Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive Lymph Nodes.', EKB Journal Management System, 7(3), pp. 77-84. doi: 10.21608/jcbr.2023.227456.1310
darwish, S., Elkady, A. The Outcomes of Concomitant Hypofractionated Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive Lymph Nodes.. EKB Journal Management System, 2023; 7(3): 77-84. doi: 10.21608/jcbr.2023.227456.1310

The Outcomes of Concomitant Hypofractionated Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive Lymph Nodes.

Egyptian Journal of Cancer and Biomedical Research
Volume 7, Issue 3, September 2023, Page 77-84  XML PDF (2.9 MB)
Document Type: Original Article
DOI: 10.21608/jcbr.2023.227456.1310
View on SCiNiTO View on SCiNiTO
Authors
sara A. darwish email 1; Asmaa Elkady2
1clinical oncology department, Tanta university
2Clinical Oncology Department, Tanta University, Egypt.
Abstract
Aim of the work: to evaluate outcome of Concomitant Hypofractionated Simultaneous Integrated Boost (SIB) Intensity-Modulated Radiotherapy (IMRT) Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive LNs in elderly patients. Patients and methods: twenty-one patients were included diagnosed with locally advanced cancer cervix ≥ 65 years old with good performance status and adequate organ functions. Eligible patients received concomitant chemotherapy in form of cisplatin monotherapy (40 mg/m2) weekly, during radiotherapy treatment in form of External Beam Radiotherapy (EBRT) with SIB due to patients` refusal or inability to receive brachytherapy (BRT). Treatment toxicity, progression free survival (PFS) and overall survival (OS) were recorded and analyzed. Results: The median age reported was 70 years, (range: 65-76 years) and the median follow up period was 35 months (ranged from 18-47 months). The OS was 90.2% at 2 years and 76.8% at 3 years. The median time to progression was 27 months (ranged from11 – 46 months). The PFS was 75.6 % at 2 years and 63.5% at 3 years. Conclusion: in locally advanced cervical cancer, SIB-IMRT could be considered an effective and safe treatment alternative in elderly patients or unavailable brachytherapy.
Keywords
Keywords: cancer cervix; radiotherapy; SIB; IMRT
Statistics
Article View: 103
PDF Download: 63